AbbVie Inc (ABBV)vsOrganiGram Holdings Inc (OGI)
ABBV
AbbVie Inc
$294.64
-0.16%
HEALTHCARE · Cap: $520.47B
OGI
OrganiGram Holdings Inc
$0.83
-0.65%
HEALTHCARE · Cap: $117.60M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 21252% more annual revenue ($66.01B vs $309.18M). OGI leads profitability with a 28.0% profit margin vs 15.7%. OGI trades at a lower P/E of 1.9x. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
OGI
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-87.6%
Fair Value
$157.25
Current Price
$294.64
$137.39 premium
Intrinsic value data unavailable for OGI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 36.6%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Revenue surging 49.4% year-over-year
Conservative balance sheet, low leverage
Keeps 28 of every $100 in revenue as profit
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -6.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 36.6%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : OGI
The strongest argument for OGI centers on P/E Ratio, Price/Book, Revenue Growth. Profitability is solid with margins at 28.0% and operating margin at -2.2%. Revenue growth of 49.4% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.6x leaves little room for execution misses.
Bear Case : OGI
The primary concerns for OGI are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a mature stock while OGI is a growth play — different risk/reward profiles.
OGI carries more volatility with a beta of 1.98 — expect wider price swings.
OGI is growing revenue faster at 49.4% — sustainability is the question.
ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 58/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
OrganiGram Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Organigram Holdings Inc. produces and sells cannabis and cannabis-derived products in Canada. The company is headquartered in Moncton, Canada.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?